175 related articles for article (PubMed ID: 24375374)
1. Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.
Hoogland AM; Verhoef EI; Roobol MJ; Schröder FH; Wildhagen MF; van der Kwast TH; Jenster G; van Leenders GJ
Prostate; 2014 May; 74(5):488-96. PubMed ID: 24375374
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
4. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression.
Ricci E; Mattei E; Dumontet C; Eaton CL; Hamdy F; van der Pluije G; Cecchini M; Thalmann G; Clezardin P; Colombel M
Prostate; 2013 Dec; 73(16):1738-46. PubMed ID: 24115186
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2.
Matsika A; Srinivasan B; Day C; Mader SA; Kiernan DM; Broomfield A; Fu J; Hooper JD; Kench JG; Samaratunga H
Pathology; 2015 Dec; 47(7):622-8. PubMed ID: 26517640
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.
Colombel M; Eaton CL; Hamdy F; Ricci E; van der Pluijm G; Cecchini M; Mege-Lechevallier F; Clezardin P; Thalmann G
Prostate; 2012 May; 72(7):713-20. PubMed ID: 21882211
[TBL] [Abstract][Full Text] [Related]
8. Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery.
Li K; Chen MK; Situ J; Huang WT; Su ZL; He D; Gao X
Chin Med J (Engl); 2013 Jan; 126(1):82-7. PubMed ID: 23286483
[TBL] [Abstract][Full Text] [Related]
9. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
Rhodes DR; Sanda MG; Otte AP; Chinnaiyan AM; Rubin MA
J Natl Cancer Inst; 2003 May; 95(9):661-8. PubMed ID: 12734317
[TBL] [Abstract][Full Text] [Related]
10. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
12. CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance.
Harris KS; Shi L; Foster BM; Mobley ME; Elliott PL; Song CJ; Watabe K; Langefeld CD; Kerr BA
Sci Rep; 2021 Jan; 11(1):1465. PubMed ID: 33446896
[TBL] [Abstract][Full Text] [Related]
13. Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins.
Venneti S; Le P; Martinez D; Xie SX; Sullivan LM; Rorke-Adams LB; Pawel B; Judkins AR
Am J Surg Pathol; 2011 Oct; 35(10):1463-72. PubMed ID: 21921784
[TBL] [Abstract][Full Text] [Related]
14. [EZH2 expression in human prostate cancer and its clinicopathologic significance].
Li J; Fan QH; Fan XS; Zhou W; Qiu Y; Qiu L
Zhonghua Nan Ke Xue; 2010 Feb; 16(2):123-8. PubMed ID: 20369694
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
Abdelrahman AE; Arafa SA; Ahmed RA
Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
[TBL] [Abstract][Full Text] [Related]
16. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma.
Foroozan M; Roudi R; Abolhasani M; Gheytanchi E; Mehrazma M
Pathol Res Pract; 2017 Jun; 213(6):612-618. PubMed ID: 28552539
[TBL] [Abstract][Full Text] [Related]
18. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
Tolonen TT; Tammela TL; Kujala PM; Tuominen VJ; Isola JJ; Visakorpi T
BJU Int; 2011 Nov; 108(9):1430-8. PubMed ID: 21592298
[TBL] [Abstract][Full Text] [Related]
19. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer.
Shen Y; Cao J; Liang Z; Lin Q; Wang J; Yang X; Zhang R; Zong J; Du X; Peng Y; Zhang J; Shi J
Cell Commun Signal; 2019 May; 17(1):50. PubMed ID: 31122254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]